Search Within

Virginia Klimek

Formats
  1. Meeting Abstract (78)
  2. Journal Article (64)
  3. Editorial (2)
  4. Research Letter (2)
  5. Book Section (1)
Groups
  1. Adult Leukemia (147)
  2. Center for Hematologic Malignancies (147)
  3. Department of Medicine (147)
  4. Hematologic Malignancies, Division of (147)
  5. GSK Faculty (44)
  6. Epidemiology and Biostatistics (36)

More Groups

People
  1. Stephen Nimer (30)
  2. Sean Devlin (26)
  3. Martin Tallman (22)
  4. Ross Levine (21)
  5. Stephen Chung (18)
  6. Elli Papaemmanuil (14)

More People

Years
  1. 2024 (2)
  2. 2023 (4)
  3. 2022 (3)
  4. 2021 (5)
  5. 2020 (8)
  6. 2019 (14)

More Years

Publications
  1. Blood (54)
  2. Leukemia Research (10)
  3. Journal of Clinical Oncology (9)
  4. Haematologica (8)
  5. Bone Marrow Transplantation (4)
  6. British Journal of Haematology (3)

More Publications

Publishers
  1. American Society of Hematology (54)
  2. Nature Publishing Group (17)
  3. American Society of Clinical Oncology (10)
  4. Elsevier Ltd (10)
  5. Ferrata Storti Foundation (8)
  6. American Association for Cancer Research (6)

More Publishers

Results (147)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
    Meeting Abstract

    Krug, U.; Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E.; more...
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • Improved survival in patients ≥60 with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
    Meeting Abstract

    Carella, A. M.; Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: Limited graft-versus-host disease without increased relapse
    Journal Article

    Tamari, R.; Chung, S. S.; Papadopoulos, E. B.; Jakubowski, A. A.; Hilden, P.; Devlin, S. M.; Goldberg, J. D.; Perales, M. A.; Ponce, D. M.; Sauter, C. S.; more...
    Biology of Blood and Marrow Transplantation (2015)

    Fulltext@MSK | Save
  • Improved survival in patients ≥60 with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 valor study
    Meeting Abstract

    Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E.; Erba, H. P.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Allogeneic transplant in patients ≥60 years of age with first relapsed or refractory acute myeloid leukemia after treatment with vosaroxin or placebo plus cytarabine: Results from VALOR
    Meeting Abstract

    Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Erba, H. P.; Pigneux, A.; Horst, H. A.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Single-cell analysis of myelodysplastic sydrome stem cells during therapy and disease progression
    Meeting Abstract

    Park, C. Y.; Vijay, P.; Chung, S. S.; Stern, D.; Klimek, V.; Mason, C. E.
    Experimental Hematology (2015)

    Fulltext@MSK | Save
  • Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study
    Journal Article

    Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E.; Erba, H. P.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplant (HCT) in patients (pts) ≥ 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR
    Meeting Abstract

    Schiller, G. J.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Erba, H. P.; Pigneux, A.; Horst, H. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells
    Journal Article

    Kotini, A. G.; Chang, C. J.; Boussaad, I.; Delrow, J. J.; Dolezal, E. K.; Nagulapally, A. B.; Perna, F.; Fishbein, G. A.; Klimek, V. M.; Hawkins, R. D.; more...
    Nature Biotechnology (2015)

    Fulltext@MSK | Save
  • Myelodysplastic syndromes, version 2.2015
    Journal Article

    Greenberg, P. L.; Stone, R. M.; Bejar, R.; Bennett, J. M.; Bloomfield, C. D.; Borate, U.; De Castro, C. M.; Deeg, H. J.; DeZern, A. E.; Fathi, A. T.; more...
    Journal of the National Comprehensive Cancer Network (2015)

    Fulltext@MSK | Save